Advertisement

The Indian Journal of Pediatrics

, Volume 85, Issue 10, pp 834–835 | Cite as

Sublingual Immunotherapy in Allergic Rhinitis: Search for a Suitable Biomarker Continues!

  • Kana Ram Jat
  • Arvind Kumar
Editorial Commentary
  • 75 Downloads

Allergic rhinitis (AR) in children is a common problem that has increased over past several decades and is frequently associated with asthma. It is due to dysregulation of immune system causing increase in inflammation and formation of specific IgE antibodies against several otherwise harmless environmental allergen/s. Among various allergens, house dust mite seems to be most common allergen for allergic rhinitis in children. Symptomatic treatment with antihistaminics (oral or nasal) and/or nasal corticosteroids is sufficient in majority of cases of AR in children. A subset of children with severe AR not responding to this conventional therapy may be benefitted by allergen-specific immunotherapy (AIT) by subcutaneous (SCIT) or sublingual (SLIT) route, the latter being increasingly used recently [1]. The guidelines have been developed for effective use of AIT in children [2].

The mechanism that leads immune tolerance in allergic rhinitis by SCIT/SLIT is complex and poorly understood...

Notes

Compliance with Ethical Standards

Conflict of Interest

None.

References

  1. 1.
    Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73:165–77.CrossRefPubMedGoogle Scholar
  2. 2.
    Pajno GB, Bernardini R, Peroni D, et al. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatr. 2017;43:13.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rogala B, Glück J. The role of interleukin-33 in rhinitis. Curr Allergy Asthma Rep. 2013;13:196–202.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Glück J, Rymarczyk B, Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm Res. 2012;61:547–50.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wang Y, Li C, Xu Y, et al. Sublingual immunotherapy decreases expression of interleukin-33 in children with allergic rhinitis. Indian J Pediatr. 2018.  https://doi.org/10.1007/s12098-018-2703-3.
  6. 6.
    Ihara F, Sakurai D, Yonekura S, et al. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy. Allergy. 2018.  https://doi.org/10.1111/all.13436.CrossRefPubMedGoogle Scholar
  7. 7.
    Nasr WF, Sorour SS, El Bahrawy AT, Boghdadi GS, El Shahaway AA. The role of the level of interleukin-33 in the therapeutic outcomes of immunotherapy in patients with allergic rhinitis. Int Arch Otorhinolaryngol. 2018;22:152–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Wang Z-x. Shi H. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis. J Huazhong Univ Sci Technol. 2017;37:407–11.CrossRefGoogle Scholar
  9. 9.
    Gotoh M, Kaminuma O, Nakaya A, et al. Identification of biomarker sets for predicting the efficacy of sublingual immunotherapy against pollen-induced allergic rhinitis. Int Immunol. 2017;29:291–300.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2018

Authors and Affiliations

  1. 1.Department of PediatricsAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations